Trial Profile

Randomized Phase II Study of Paclitaxel With or Without the Anti-IGF-IR mAb Cixutumumab (IMC-A12) as Second Line Treatment for Patients With Metastatic Esophageal or GE Junction Cancer

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 14 Apr 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Cixutumumab (Primary) ; Paclitaxel
Indications Adenocarcinoma; Adenosquamous carcinoma; Gastric cancer; Oesophageal cancer; Squamous cell cancer
Focus Therapeutic Use

Most Recent Events

20 Mar 2025 Planned End Date changed from 7 Mar 2025 to 19 Mar 2026.
07 Sep 2023 Results published in the Oncologist
28 Jul 2014 Planned primary completion date changed from 1 Aug 2014 to 1 Jul 2014 as reported by ClinicalTrials.gov record.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com